Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | JNJ-87801493 |
| Trade Name | |
| Synonyms | JNJ 87801493|JNJ87801493 |
| Drug Descriptions |
JNJ-87801493 is a bispecific antibody targeting CD20 on B-cells and CD28 on T-cells, which potentially enhances T-cell activation and inhibits tumor growth (Blood (2024) 144 (Supplement 1): 1408). |
| DrugClasses | CD20 Antibody 26 CD28 Antibody 12 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| JNJ-75348780 + JNJ-87801493 | JNJ-75348780 JNJ-87801493 | 0 | 1 |
| JNJ-80948543 + JNJ-87801493 | JNJ-80948543 JNJ-87801493 | 0 | 1 |
| JNJ-87801493 | JNJ-87801493 | 0 | 0 |